conference are as to been close forward. contract we with you regular for our we thank were earnings calls the the Illumina of us we at terminate to last most resuming merge to afternoon that for with It's beginning since contract going Good of period. agreed today. Trevin. and Illumina Thanks, year, under a this year-and-a-half call, Since quarterly earnings joining
XXXX highest QX XX% represents in of in systems of and quarter financial full highlights revenue detail for service which up will million describe our results. We XXXX. QX our shortly. history revenue some $XX.X the year was and from in by product This and of and generated quarter, service of sales with start Sequel I'll I II fourth more and driven product consumables, our the
For revenue XX% million the $XX.X $XX.X revenue in to in from for XXXX. our year, the XXXX. XXX% product Instrument and was quarter grew service from fourth million, XXXX up QX, $XX.X million
Instrument million, was We installed XXXX. year XX% our revenue the instrument new of For the Sequel $XX.X revenue Sequel sales driven by up II strong II of of was XXX with from year, growth system. base systems. an in The the ended
from for X% Consumable was the from XXXX, QX but sequentially fourth revenue XX% $X.X up XXXX. QX quarter down million,
million, totaled down $XX.X consumable For the compared our with year, revenue XXXX. XX%
past were Sequel systems customers this II sales favor of by in of year systems. heavily impacted I Sequel consumable decreasing usage Our their older acquiring
already comprised the revenue While consumables consumables of more we total of year, less sales I over Sequel customers to XXXX. this to fourth half should the headwind pronounced, to of Sequel consumables as be from Sequel quarter revenue in move II growth expect II our
the Gross from in up QX, when XX% margin. Roche gross from in and was from we history, margin fourth highest XXXX, periods This XX% XX%, recognize excluding the at for QX, XXXX. revenue XXX% quarter in margin represents up our quarterly collaboration
$XX agreement quarter, we with merger from the fourth received as other during income. million Illumina, of terms the we the recorded Per which Illumina
details to cash the later for will of end the $XXX,XXX As on maintained in provide forward Ben $XX the position breaking balance our cash even we came quarter. within of more the of We the close and call. investments result, a at year going million.
signed longer process already of spent on review was questions from having we with outside could fees the much the our million provide spent answering providing comments merger, eventual I'll nor than expected. be. taking what November end or few Illumina certainty and it XXXX. know the on By to would in the not We better the X, originally the of sales predict termination authorities and we Kingdom. related the months, outcome of either or $XX originally merger part information much a did agreement XX The agreement Illumina. antitrust regarding close Now, we the merger XXXX, United I to and with longer to take, the legal professional do U.S. how
both the agreement. clearance Illumina merger reverse from X advances the that on previously amended instead Illumina we've and mind We agreement. agreed receiving with day in in the of to this January received with continuing termination fee Illumina we from continuation merger same bodies, With been a million were described that regulatory terminate pursue to $XX
the merger agreement end by in million agreement. the termination of QX would with conjunction the total, the In and we receive Illumina from this of year, $XXX
during were we time. a not many position an business the disappointed we we that independent and of company are running in completed, could forward. are today year, financial past a as accomplishments the PacBio maintained proud While driving we this Meanwhile, achieved during on be we the that good continue to merger focus
we general PacBio's commercial of At to and Sequel The last the success the base highlight installed mid-April. of System system a smoothly measures. in fastest II an the December, here. end of ramp new with XXX Sequel Systems, launch a with in launch early a which history. a represents of the number By of to progressed had by of we customers of II like some access five began program year, start an I'd was accomplishments those
our us of experience reliability. important a start was customers system reliable exceeded from and wanted the we and minimal targets to customer measures the We success most One expectations. of for highly downtime system with
into Sequel sequencing we customers, experience on integrate lots Systems their was access in to breaking products, II commented it how early of them new Our have seamless operations. for their
which System's and surprise for I it yield The and initial customers. common Systems. measured performance out Cell the from was RS also of II some Sequel issues A box sequencing a of sophisticated our significant pleasant matched these the of had who systems that, of them sequencing has message projections with of users was worked right by the initial Sequel expectations earlier our per SMRT our launch exceeded or as experienced
have from of their XXXX, By generating the is Several on the data XX drawback after so a average end Sequel per data they the Sequel Systems. were consumables. I cannibalized it have our systems Sequel of of with successful months few receiving with sales units. of users we've SMRT the and Sequel I first yields our dramatically previous already compared quality launch II customers amount pleased had purchased Cell, just II throughput been within times that their The additional of only on
sales. sales the our XX% consumable fourth of Sequel sales less of By quarter XXXX, our instrument and XX% only than I of contributed
have Sequel While sequencing customer the consumable II rapid of us limited is exceeded to consumable larger increased projections access a our early I projects with allowing consumable in noted I. have of as could and our decrease the sales. of eclipsed set growth sales the broader Sequel overall Sequel earlier, Sequel revenue now the Systems II I than performance have sales we Sequel XXXX,
in a our Life increasing many projects. that sequencing Sequencing Darwin Trust United system customers technology, to species is down allowing plants and is targeting of well-funded animals play role which throughput the Sanger sequence to The larger SMRT significant to Tree cost our benefit of thus brings Institute, is heading it The of in with the Wellcome the XXXXX of Project, Kingdom.
doing With the Sequel Systems, the setting in to power start are they their of so pipeline II volume. up
closely the prepare libraries protocols are the sample We for with group to Sequencing. sequencing Sanger SMRT working improve used preparation to
of de assemblies in Annoroad as improved from animal and a plant increased such sequencing focused produce individual reference used and HistoGenetics Other significantly tiny China Sequel programs level also human the variety as including protocols a Labs, performance. on Jackson One novo single System's small USDA, programs their specimens on of have been at these expanded based those mosquito. insect to projects has II a as The HudsonAlpha,
assemblies see to whole technology of structural use larger-scale variants generation both human greater of present genome our projects large for study for Moreover, have reference in and in we the of populations. high-quality begun genome the
the conjunction results last PacBio's Sequel began for accurate II highly becoming HiFi generating long for introduction genome of de SMRT a from standard applications System method promoting year, Sequencing. sequencing reads of high-quality with creating including quickly number is we the also novo protocol and the other In in it and assemblies a
the unambiguous sequence circle, the preparation consensus contain highly on of DNA generation molecule individual ability to molecules sequence Sequencing repetitive DNA times comparison This the SMRT themselves our HiFi the sample passes generated around accurate are passes individual may read around a by of in allows errors. circular many of Sequencing even an protocols. though for based reads
with CCS or Sequencing and the several method with Sequencing HiFi high to been reads Consensus in fragments been used has applications. available accuracy obtain SMRT Circular shorter used sequence molecule The to single has always
in HiFi XX,XXX DNA short-read fragments with over single to improvements link traditional with data. generate XX% fragments operate base long accuracy the that comparable from base accuracy reads method from DNA XX.X%. methods, and software in sample the Our CCS to sequencing now allow prep an up chemistry molecule pairs than and that on much on higher accuracy long-read to This only methods individual sequencing XXX reads is obtained typical pairs average
faster, make but subsequent requiring as final lower de less analyses and reads. compute cost high it with time starting assembly such reads Starting assemblies and far complete, much with longer produces novo much accuracy and such more contiguous more long accuracy,
assemblies Moreover, produce XXX pair use to greater than data. the with of can consensus without reads base are accurate HiFi polish the highly need the that short-read XX.XXX% level at or
molecules pair with variant DNA evolving include rare can greater a obtained even large a to involve gene In of average single analysis cases HiFi be Examples close in panels just or transcript discrimination isoform metagenome allowing samples. thousand few of of with a long. related reads bacterial tumor XXX base and molecules than and with base projects sequencing populations, Many an normal of sequences. population sequence these targeted pairs virus isolates, accuracy of fragments
Berry we had year regulatory with a highlight for to for and success II clearance is previous Another for engaged has consumables applications System similar with distribute China. than Genomics past China Illumina. and this obtain Berry it Sequel in partnership has with in Genomics our clinical that
for for is to sequencer clinical in suited Illumina clearance obtaining NIPT Sequel our II such the Berry an sells it and obtained in SMRT for applications our clearance which technology. for process as analyses of China Systems
for been has PacBio of Systems. years both now II our Sequel Sequel and important our an in providing Berry sequencing services customer several with I China
are We them clinical in PacBio to bring China. into applications to sequencing looking with products forward working
This of launch to chemistry XXXX that ago, we prep months commercial XX less full performance. began throughput, lengths initial able similar parameters and plan and its the we QX a though sequencing higher faster analysis upgrades read to of times. include analysis were more. software of extend improvements that than upgrades performance should sample II chemistry its even collection to sequencing year we System These added Even allow longer in Sequel release
the We're further streamline required sample protocols and also to sequencing amount prep our generate even of to the libraries. starting working minimize sample to DNA
not continued protocol host to sample that reference to Such have capabilities scientists using is of sequencing. XXX long-read such reference millionth could to did that a amenable allow DNA. gram. tiny with of as of prep a work a high-quality We the picogram assemblies, organisms picograms of of should Sanger a millionth a assemblies enable think for develop little genome A as quality
expansion academic also sales read results our of of working and to are commercial completion development full advantage characteristics. Illumina, with of we HiFi take institutions accomplished successful from our several of our Anticipating XXXX by We in acquisition software experts to bioinformatics analysis significant our and organizations. marketing without continue
up. II it Sequel wider sequencing success of the the the advantage of the II. With our that to is timing opportunities difficult, opens hire better to train sophisticated in System, as of Predicting need both commercial the organization in systems to expansion takes personnel the to such and sell because time investment this results order somewhat it sales our feel we initial take Sequel expand we of
we centered normal China our and until in resumes. still roughly represented the potential a are largely Recall and revenue outbreak be of business. base In of historically may quarter outbreak coronavirus that the subsides inaccessible assessing our shorter the commerce term, impact the that on total China
it as We forward. encouraged dedicated feel the cash continued feel base early development we are move positioned efforts to our business. long-term of SMRT in employee the and our of are and that that expansion opportunities Nevertheless, continue our we is its for technology by future Sequencing capabilities resources, we remarkable excited our still of our we strongly with
my results. initial I'll over provide concludes financial That more remarks. on now Susan to to details it turn our
